Share Price | Tenaya Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Tenaya Therapeutics, Inc.?

Market Cap: As of Jun 18, Tenaya Therapeutics, Inc. has a market capitalization of 93.37 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Tenaya Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -105.76 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 92.85 million and total assets of 123.33 million.

Q: What does Tenaya Therapeutics, Inc. do?

Overview:Tenaya Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025)- Market cap: USD 93.37 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.71- Return on Equity: -88.58%- Price to Book: 0.78Contact Details:No Company Details Available.

Q: Is Tenaya Therapeutics, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Tenaya Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, but the weekly RSI is bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the monthly Bollinger Bands show a mildly bearish stance. The KST is bullish on a weekly basis but bearish monthly, and the Dow Theory indicates a mildly bullish trend on the weekly chart with no trend monthly. In terms of performance, the stock has returned -7.69% year-to-date compared to the S&P 500's 12.22%, and it has significantly underperformed over the past year with a return of -34.65% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish.

Results Declared: Tenaya Therapeutics, Inc. has declared results on 06 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

572.32 k

Shareholding (Dec 2025)

FII

3.76%

Held by 44 FIIs

DII

79.58%

Held by 19 DIIs

Promoter

7.09%

How big is Tenaya Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Tenaya Therapeutics, Inc. has a market capitalization of 93.37 million, with net sales of 0.00 million and a net profit of -105.76 million over the latest four quarters. The company reported shareholder's funds of 92.85 million and total assets of 123.33 million as of Dec 24.

View full answer

What does Tenaya Therapeutics, Inc. do?

22-Jun-2025

Tenaya Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $27 million and a market cap of $93.37 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -88.58%.

View full answer

Is Tenaya Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Tenaya Therapeutics, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly year-to-date and over the past year.

View full answer

Compare Tenaya Therapeutics, Inc. with Similar Stocks

Verrica Pharmaceuticals, Inc.Gossamer Bio, Inc.Omeros Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 186 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.64

Return on Equity

-113.74%

Price to Book

2.24

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Mar 2026)

Net Profit:

-19 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.55%

6 Months

-33.72%

1 Year

88.58%

2 Years

-81.6%

3 Years

-87.52%

4 Years

-88.33%

5 Years

0.0%

Tenaya Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-26.40%

EBIT to Interest (avg)

-100.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.72

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.43%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.24

EV to EBIT

-1.36

EV to EBITDA

-1.50

EV to Capital Employed

4.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-329.72%

ROE (Latest)

-113.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 31 Schemes (9.57%)

Foreign Institutions

Held by 44 Foreign Institutions (3.76%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 28.25% vs 16.46% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.30",
          "val2": "-24.90",
          "chgp": "26.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.30",
          "val2": "-26.90",
          "chgp": "28.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-89,177.80%",
          "val2": "0.00%",
          "chgp": "-8,917.78%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 18.45% vs 10.48% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-84.90",
          "val2": "-107.50",
          "chgp": "21.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-90.60",
          "val2": "-111.10",
          "chgp": "18.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-18.30

-24.90

26.51%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-19.30

-26.90

28.25%

Operating Profit Margin (Excl OI)

-89,177.80%

0.00%

-8,917.78%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 28.25% vs 16.46% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-84.90

-107.50

21.02%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-90.60

-111.10

18.45%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 18.45% vs 10.48% in Dec 2024

All Annual Results

Company CV

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available